These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 28927824)

  • 1. Cellular therapy for multiple pathogen infections after hematopoietic stem cell transplant.
    Sutrave G; Blyth E; Gottlieb DJ
    Cytotherapy; 2017 Nov; 19(11):1284-1301. PubMed ID: 28927824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Ma CK; Blyth E; Clancy L; Simms R; Burgess J; Brown R; Deo S; Micklethwaite KP; Gottlieb DJ
    Cytotherapy; 2015 Oct; 17(10):1406-20. PubMed ID: 26349000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigenic competition in the generation of multi-virus-specific cell lines for immunotherapy of human cytomegalovirus, polyomavirus BK, Epstein-Barr virus and adenovirus infection in haematopoietic stem cell transplant recipients.
    Roubalová K; Němečková Š; Kryštofová J; Hainz P; Pumannová M; Hamšíková E
    Immunol Lett; 2020 Dec; 228():64-69. PubMed ID: 33031870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.
    Neuenhahn M; Albrecht J; Odendahl M; Schlott F; Dössinger G; Schiemann M; Lakshmipathi S; Martin K; Bunjes D; Harsdorf S; Weissinger EM; Menzel H; Verbeek M; Uharek L; Kröger N; Wagner E; Kobbe G; Schroeder T; Schmitt M; Held G; Herr W; Germeroth L; Bonig H; Tonn T; Einsele H; Busch DH; Grigoleit GU
    Leukemia; 2017 Oct; 31(10):2161-2171. PubMed ID: 28090089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation.
    Kaeuferle T; Krauss R; Blaeschke F; Willier S; Feuchtinger T
    J Hematol Oncol; 2019 Feb; 12(1):13. PubMed ID: 30728058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
    Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
    Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.
    Tzannou I; Papadopoulou A; Naik S; Leung K; Martinez CA; Ramos CA; Carrum G; Sasa G; Lulla P; Watanabe A; Kuvalekar M; Gee AP; Wu MF; Liu H; Grilley BJ; Krance RA; Gottschalk S; Brenner MK; Rooney CM; Heslop HE; Leen AM; Omer B
    J Clin Oncol; 2017 Nov; 35(31):3547-3557. PubMed ID: 28783452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early cytomegalovirus reactivation leaves a specific and dynamic imprint on the reconstituting T cell compartment long-term after hematopoietic stem cell transplantation.
    Lugthart G; van Ostaijen-Ten Dam MM; Jol-van der Zijde CM; van Holten TC; Kester MG; Heemskerk MH; Bredius RG; van Tol MJ; Lankester AC
    Biol Blood Marrow Transplant; 2014 May; 20(5):655-61. PubMed ID: 24462981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
    Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
    Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma.
    Pfeffermann LM; Pfirrmann V; Huenecke S; Bremm M; Bonig H; Kvasnicka HM; Klingebiel T; Bader P; Rettinger E
    Cytotherapy; 2018 Jun; 20(6):839-850. PubMed ID: 29754771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CMV-, EBV- and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome.
    Sukdolak C; Tischer S; Dieks D; Figueiredo C; Goudeva L; Heuft HG; Verboom M; Immenschuh S; Heim A; Borchers S; Mischak-Weissinger E; Blasczyk R; Maecker-Kolhoff B; Eiz-Vesper B
    Biol Blood Marrow Transplant; 2013 Oct; 19(10):1480-92. PubMed ID: 23891747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for transplantation-associated viral infections.
    Roddie C; Peggs KS
    J Clin Invest; 2017 Jun; 127(7):2513-2522. PubMed ID: 28628043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults.
    Galletta TJ; Lane A; Lutzko C; Leemhuis T; Cancelas JA; Khoury R; Wang YM; Hanley PJ; Keller MD; Bollard CM; Davies SM; Grimley MS; Rubinstein JD
    Transplant Cell Ther; 2023 May; 29(5):305-310. PubMed ID: 36736781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogen-Specific T Cells Beyond CMV, EBV and Adenovirus.
    Jiang W; Withers B; Sutrave G; Clancy LE; Yong MI; Blyth E
    Curr Hematol Malig Rep; 2019 Aug; 14(4):247-260. PubMed ID: 31228095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation.
    Maffini E; Giaccone L; Festuccia M; Brunello L; Busca A; Bruno B
    Expert Rev Hematol; 2016 Jun; 9(6):585-96. PubMed ID: 27043241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells.
    Tischer S; Priesner C; Heuft HG; Goudeva L; Mende W; Barthold M; Kloeß S; Arseniev L; Aleksandrova K; Maecker-Kolhoff B; Blasczyk R; Koehl U; Eiz-Vesper B
    J Transl Med; 2014 Dec; 12():336. PubMed ID: 25510656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
    Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
    J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital.
    Fleming T; Dunne J; Crowley B
    J Med Virol; 2010 Mar; 82(3):433-40. PubMed ID: 20087937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive T Cell Therapy for Epstein-Barr Virus Complications in Patients With Primary Immunodeficiency Disorders.
    McLaughlin LP; Bollard CM; Keller MD
    Front Immunol; 2018; 9():556. PubMed ID: 29616044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of adoptive T-cell therapy in treating cytomegalovirus infections post-haematopoietic stem cell transplantation: A systematic review and meta-analysis.
    Taherian MR; Azarbar P; Barkhordar M; Toufani S; Aliabadi LS; Bahri T; Ahmadvand M; Yaghmaie M; Daneshvar A; Vaezi M
    Rev Med Virol; 2024 Jul; 34(4):e2558. PubMed ID: 38878003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.